During the last session, Sangamo Therapeutics Inc (NASDAQ:SGMO)’s traded shares were 11.22 million, with the beta value of the company hitting 1.21. At the end of the trading day, the stock’s price was $1.70, reflecting an intraday loss of -14.57% or -$0.29. The 52-week high for the SGMO share is $2.30, that puts it down -35.29 from that peak though still a striking 82.94% gain since the share price plummeted to a 52-week low of $0.29. The company’s market capitalization is $353.98M, and the average intraday trading volume over the past 10 days was 20.4 million shares, and the average trade volume was 9.12 million shares over the past three months.
Sangamo Therapeutics Inc (SGMO) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.12. SGMO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Sangamo Therapeutics Inc (SGMO) registered a -14.57% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -14.57% in intraday trading to $1.70, hitting a weekly high. The stock’s 5-day price performance is 14.09%, and it has moved by 108.21% in 30 days. Based on these gigs, the overall price performance for the year is 169.76%. The short interest in Sangamo Therapeutics Inc (NASDAQ:SGMO) is 18.22 million shares and it means that shorts have 7.21 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 85.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $19 respectively. As a result, SGMO is trading at a discount of -1017.65% off the target high and -194.12% off the low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Statistics show that Sangamo Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sangamo Therapeutics Inc (SGMO) shares have gone up 225.67% during the last six months, with a year-to-date growth rate more than the industry average at 20.34% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 94.90% this quarter and then jump 85.30% in the quarter after that. In the rating firms’ projections, revenue will decrease -69.20% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.94M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 15.31M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.4M and 2.04M respectively. In this case, analysts expect current quarter sales to grow by 72.50% and then jump by 649.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.96%. While earnings are projected to return 68.83% in 2024.
SGMO Dividends
Sangamo Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Sangamo Therapeutics Inc insiders own 2.38% of total outstanding shares while institutional holders control 42.21%, with the float percentage being 43.24%. WASATCH ADVISORS LP is the largest shareholder of the company, while 160.0 institutions own stock in it. As of 2024-06-30, the company held over 20.09 million shares (or 11.1403% of all shares), a total value of $7.2 million in shares.
The next largest institutional holding, with 14.06 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 7.7963% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.04 million.
